Oppenheimer Maintains Outperform on Mirati Therapeutics, Raises Price Target to $62
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson maintains an Outperform rating on Mirati Therapeutics (NASDAQ:MRTX) and raises the price target from $56 to $62.
August 09, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst has maintained an Outperform rating on Mirati Therapeutics and raised the price target from $56 to $62.
The news is directly related to Mirati Therapeutics. The maintained Outperform rating and increased price target by Oppenheimer analyst could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100